In line / mixed
Earnings were protected and the reset was less severe than feared, while standalone WATCHMAN volumes deteriorated.
[AS-EXP-031]Boston Scientific
Q1 2026: A feared guidance cut de-risked the year and produced a relief rally, but WATCHMAN weakness made the recovery fragile.
ResultIn line / mixedGuidanceMixed / newly framedEnvironmentmixed
Investment snapshot
What happened and why it mattered
Mixed / newly framed
The annual framework incorporated a slower growth profile without breaking the long-term portfolio case.
[AS-EXP-031]Deceleration
The annual framework incorporated a slower growth profile without breaking the long-term portfolio case.
[AS-EXP-031]Qualitative
The stock rallied because the reset removed a near-term overhang, then weakened as the WATCHMAN demand problem deepened.
[AS-ME-087]Results versus expectations
The print and the three most important read-throughs
Earnings were protected and the reset was less severe than feared, while standalone WATCHMAN volumes deteriorated.
- 1
Earnings were protected and the reset was less severe than feared, while standalone WATCHMAN volumes deteriorated.
Guidance bridge
GuidanceMixed / newly framedLatest outlook and KPI implications
The annual framework incorporated a slower growth profile without breaking the long-term portfolio case.
| Metric | Prior | Latest | Consensus | Delta | Status | Reason / implication |
|---|---|---|---|---|---|---|
| FY26 organic growth | 10.0–11.0% | 6.5–8.0% | ~6.8% (Bloomberg) | −275bps midpoint | Updated | WATCHMAN, EP competition, Urology |
| FY26 adjusted EPS | $3.43–3.49 | $3.34–3.41 | $3.38 | −$0.08 midpoint | Updated | Softer high-margin mix, offset by tax |
| FY26 adj. operating margin | +50–75bps | +50–75bps (maintained) | ~28.4% | No change | Maintained | OpEx leverage, spend controls |
| FY26 adj. gross margin | ~in line w/ FY25 (70.6%) | Slightly below FY25 | 70.4% | Lowered | Lowered | Lower product-mix benefit, tariffs, supply-chain investment |
| FY26 adj. tax rate | ~12.5% | ~12.0% | ~12.2% | −50bps | Updated | Latest tax legislation |
| FY26 free cash flow | ~$4.2B | ~$4.2B (later ~$4B) | ~$4.1B | Broadly maintained | Maintained | Strong FCF conversion |
Management signal — paraphrased
The annual framework incorporated a slower growth profile without breaking the long-term portfolio case.
Implied cadence
The annual framework incorporated a slower growth profile without breaking the long-term portfolio case.
Stock reaction
Why the shares moved
The stock rallied because the reset removed a near-term overhang, then weakened as the WATCHMAN demand problem deepened.
- The stock rallied because the reset removed a near-term overhang, then weakened as the WATCHMAN demand problem deepened.
Did the reaction persist?
[AS-ME-087]Not independently calculated in the compact record.
Adjusted-close reaction
Independent return windows were not embedded in this compact record. The reaction assessment is qualitative.
Source-reported qualitative reaction; no independent price series embeddedMarket environment delta
EnvironmentmixedWhat management said about the operating backdrop
A feared guidance cut de-risked the year and produced a relief rally, but WATCHMAN weakness made the recovery fragile.
- Customer demandMixed
Strong concomitant demand but a deceleration in standalone WATCHMAN procedures as practice patterns shift
OutlookConcomitant to keep growing; standalone weak near-termKPI implicationWATCHMAN FY26 cut to mid-teens; ~$140M lower revenueManagement interpretation · High confidence · [117] - Volumes / proceduresMixed
WATCHMAN grew 19% but US volumes pressured as quarter progressed, first decline from February; EP growth on strong catheter utilization
OutlookStandalone soft; hospitals prioritizing higher-value casesKPI implicationUS WATCHMAN low-to-mid teens FY26Disclosed fact · High confidence · [118] - Regional / ChinaMixed
US +11% (5 of 8 units double-digit); EMEA +1% on ACURATE/POLARx and Middle East; China strong ex-VBP but Urology/Vascular hit by VBP
OutlookChina EP momentum continues on FARAWAVE NAV/persistent AFKPI implicationRegional mix pressures FY26 organicDisclosed fact · Medium confidence · [122]
- Channel / commercial modelWorsening
Sacral neuromodulation hit by commercial-model disruption; adding focused reps directly on WATCHMAN to augment territory reps
OutlookSequential Urology improvement, not market growth in 2026KPI implicationUrology guide cut to low-to-mid single digitManagement interpretation · Medium confidence · [119] - Supply availability / inventoryMixed
AXIOS better than anticipated on ramped supply; Endoscopy to navigate transient 2Q supply disruption, resolving 2H26; SEISMIQ IVL ramping
OutlookEndoscopy supply resolution in 2H26KPI implicationTransient 2Q Endoscopy headwindDisclosed fact · Medium confidence · [120] - Input costs / labor / marginWorsening
GM down 100bps y/y to 70.5% on tariffs plus POLARx discontinuation inventory charge; heavy Urology rep hiring/training
OutlookFY26 GM now slightly below 2025KPI implication~$35M FY EP POLARx drag; GM guide loweredDisclosed fact · High confidence · [121]
- Competition (PFA/EP)Worsening
Now sees increased competition from Medtronic, J&J and Abbott, with more share erosion than previously anticipated but retained leadership
Outlook2026 a "transition year"; return to share gains in 2027+ via Farawave Ultra, Faraflex, ICEKPI implicationFY26 global EP cut to ~10% from 15%+; ~$180M lower EP revenueManagement interpretation · High confidence · [115] - Pricing / reimbursementWorsening
Reimbursement cut hitting interventional cardiologists in structural heart; evolving reimbursement softening standalone WATCHMAN
OutlookOngoing pressure on standalone economicsKPI implicationContributes to WATCHMAN standalone decelerationManagement interpretation · Medium confidence · [116]
Evidence and confidence
Source map
No material gap recorded.
AlphaSense synthesis
Open source ↗Official company source
Open source ↗AlphaSense market-environment synthesis
Open source ↗